期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

司美格鲁肽治疗2型糖尿病伴代谢相关性脂肪性肝病1例 被引量：1

Type 2 diabetic patient with metabolically associated fatty liver disease treated by semaglutide:a case report
原文传递
导出
摘要 报道1例2型糖尿病(T2DM)合并代谢相关性脂肪性肝病(MAFLD)患者使用司美格鲁肽的诊疗过程。患者为63岁男性,因诊断糖尿病18年,血糖控制差半年就诊。患者身高1.68 m,体重79 kg,体重指数28 kg/m^(2)。既往合并冠心病、高血压。患者入院采用地特胰岛素联合二甲双胍及阿卡波糖降糖治疗,血糖控制差,考虑患者明确诊断冠心病,合并MAFLD、肥胖、高血压、血脂异常,为使患者获得多重获益,减少用药频次,提高依从性,将原有降糖方案中的基础胰岛素更换为司美格鲁肽降糖治疗,由起始剂量0.25 mg/周逐渐增加至1.0 mg/周,并停用阿卡波糖,患者血糖控制更加理想,MAFLD程度减轻,体重减轻,血压有所下降,血脂谱较前改善。患者对治疗效果满意。
作者 李婧 李小凤 Li Jing;Li Xiaofeng(Endocrine Diabetes Hospital,Shaanxi Provincial People′s Hospital,Xi′an 710068,China)
机构地区 陕西省人民医院内分泌糖尿病病院
出处 《中华糖尿病杂志》 CAS CSCD 北大核心 2023年第S02期99-101,共3页 CHINESE JOURNAL OF DIABETES MELLITUS
关键词 糖尿病 2型 代谢相关性脂肪性肝病 司美格鲁肽
分类号 R587.1 [医药卫生—内分泌] R575.5 [医药卫生—消化系统]
作者简介 通信作者:李小凤,Email:linfm67@163.com
  • 相关文献

参考文献1

二级参考文献10

  • 1Lili Zhang,Mengliu Yang,Hong Ren,Huaidong Hu,Guenther Boden,Ling Li,Gangyi Yang.GLP ‐1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c‐ JNK[J].Liver Int.2013(5)
  • 2M. J. Armstrong,D. D. Houlihan,I. A. Rowe,W. H. O. Clausen,B. Elbr?nd,S. C. L. Gough,J. W. Tomlinson,P. N. Newsome.Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program[J].Aliment Pharmacol Ther.2012(2)
  • 3A. de Souza Bruno,M. H. Rodrigues,M. C. B. Alvares,J. Nahas-Neto,E. A. Petri Nahas.Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women[J].Climacteric.2014(4)
  • 4Justin J. Wilkins,Michel Dubar,Bernard Sébastien,Christian Laveille.A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes[J].Journal of Clinical Pharmacology.2014(3)
  • 5Hui Chen,David Simar,Katherine Pegg,Sonia Saad,Clovis Palmer,Margaret J. Morris.Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents[J].Diabetologia.2014(3)
  • 6Yao Dai,Jawahar L. Mehta,Mingwei Chen.Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation[J].Cardiovascular Drugs and Therapy.2013(5)
  • 7N. D. Hopkins,D. J. Cuthbertson,G. J. Kemp,C. Pugh,D. J. Green,N. T. Cable,H. Jones.Effects of 6 months glucagon‐like peptide‐1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients[J].Diabetes Obes Metab.2013(8)
  • 8Christina Daousi,Jonathan H. Pinkney,Jacqueline Cleator,John P. Wilding,L.R. Ranganath.Acute peripheral administration of synthetic human GLP-1 (7–36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?[J].Regulatory Peptides.2013
  • 9Yuli Cai,Xiaorong Hu,Bo Yi,Ting Zhang,Zhongyuan Wen.Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression[J].Molecular Biology Reports.2012(12)
  • 10Nitika A. Gupta,Vasantha L. Kolachala,Rong Jiang,Carlos Abramowsky,Rene Romero,Nimita Fifadara,Frank Anania,Stuart Knechtle,Allan Kirk.The Glucagon-Like Peptide-1 Receptor Agonist Exendin 4 Has a Protective Role in Ischemic Injury of Lean and Steatotic Liver by Inhibiting Cell Death and Stimulating Lipolysis[J].The American Journal of Pathology.2012(5)

共引文献26

同被引文献14

中华糖尿病杂志
2023年 第S02期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部